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                                      Serious mental illness and smoking cessation 
                                                A discussion paper 
Abstract 
Smoking rates among individuals with severe mental illness (SMI) are significantly higher than in 
the general population. Contrary to common perception, individuals with SMI have been shown to 
be motivated to quit smoking. This paper discusses and synthesises current literature on smoking 
among individuals with serious mental illness (SMI) and contributes to the debate about the 
significant role mental health professionals can play in targeting the effective cessation therapies 
towards smokers with SMI. Serious mental illnesses include Schizophrenia, Paranoid and other 
psychotic disorders, psychotic depression, Bipolar affective disorder, Major depression. 
Key words: Mental illness, Serious mental illness (SMI), Tobacco dependency, smoking, smoking 
cessation therapies 
Introduction 
This paper summarises and synthesises current literature on reasons for excessive smoking 
rates in individuals with SMI, smoking cessation interventions and implications for practice are 
discussed. Smoking cessation interventions receive little attention in mental health settings 
despite many patients being heavy smokers (Szatkowsk and McNeill, 2015). Individuals with SMI 
smoke significantly more, have increased levels of nicotine dependency and are therefore at 
even greater risk of smoking-related harm. Smoking rates among people with SMI are three times 
higher than the general population (Wardle et al. 2011, Office for National Statistics, 2016). 
Campion et al. (2008) in their study found that patients suffering from schizophrenia smoke 
significantly more than smokers with other mental disorders. Similarly, people with SMI living in 
health and social care institutions usually smoke more than the general population and, a review 
by Mental Health Foundation (2016) found that 85% of people with SMI lived in hospital and 
residential dwellings with an average smoking rate of 72% recorded for this group. Similarly, in 
the United States, a study by Lasser et al. (2010) found excessive smoking rates in people with 
SMI in residential homes. The scale of this association in the UK tends to rise cumulatively with 
the severity of mental illness particularly amongst inpatients (Health and Social care Information 
Centre, 2007). 
In the UK data on smoking prevalence among people with mental disorders has mainly come 
from a series of Adult Psychiatric Morbidity Surveys (APMS) conducted in 1993, 2000, 2007 and 
recently in 2014 (Jenkins et al. 2009; McManus et al. 2016). The Adult Psychiatric Morbidity 
Survey (APMS) conducted in 2007 found higher rates of smoking among those with a diagnosis 
of a mental illness or those using psychotropic medication. Smoking prevalence within specific 
diagnostic groups ranged from 57% (those who have attempted suicide in the last year of the 
APMS), 56% (probable psychosis), 34% (major depression and other common mental disorders) 
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to 25% (eating disorders). Recently, results from the 2014 Adult Psychiatric Morbidity Survey 
found a strong association between smoking and suffering with a common mental health disorder 
(CMD), with a higher incidence (31.3%) of mental illness found in people smoking 15 or more 
cigarettes a day compared with 23.3% of those smoking fewer than 15 cigarettes a day 
(McManus et al. 2016).  
Why do Individuals with serious mental illness (SMI) smoke more? 
Patients with significantly greater levels of neurotic and psychotic symptoms are likely to smoke 
more compared to those with less severe symptom profile (Action on Smoking and Mental 
Health, 2011;Mental Health Foundation, 2016).The heightened levels of psychosis are usually 
associated with prolonged periods of anxiety and distress and for smokers with SMI, nicotine 
introduction stimulates dopamine production in the brain which enhances pleasurable feelings 
and relaxation (Novak et al. 2010). Equally, Patkar et al. (2002) claims that patients smoke to 
‘self-medicate’ as nicotine possibly reduces the severity of psychiatric symptoms and side effects 
of antipsychotic drugs. However, the ‘self-medication’ theory commonly proposed could be 
related to increased tobacco dependence as smokers need higher levels of nicotine to feel 
normal. Ratschen et al. (2011) emphasise that as the relief from nicotine withdrawal is usually 
temporary, continued smoking can further exacerbate mental wellbeing in the long run. 
A survey conducted by McNally et al. (2006) among mental health staff found less favourable 
attitudes than general staff to smoke free clinical settings. Unsurprising, a study by Hehir et al. 
(2013) in a mental health facility found staff who smoked were more negative about the possibility 
that patients would succeed at smoking cessation in the long-term compared to non-smoking 
staff. Furthermore, due to the lax smoking culture, Ratschen et al. (2011) found that smoking acts 
as the machinery for many of the rules of communication and practices in mental health settings. 
Even though smoke free policies are part of NHS organisational ethos, cigarettes are still used 
often as tools to reward or punish patients by staff in mental health settings (Ratschen et al. 
2011; Johnson et al. 2010). Such practices can undermine implementation of smoking cessation 
strategies as they serve to reinforce rather than address smoking behaviour and do little to 
support smokers with mental illness to quit.  
Individuals with SMI are vulnerable to misleading messages promoted by the tobacco industry; 
research shows that the tobacco industry specifically targets these patients (Apollonio and 
Malone, 2005). Equally, Boyd and Lasser (2001) believe that the tobacco industry may indirectly 
or directly target psychologically vulnerable groups as part of the tobacco advertising. It is likely 
that individuals with SMI have difficulty to recognise erroneous claims and consequences of 
tobacco advertising. Unsurprisingly, smokers with schizophrenia in the UK contribute £139m to 
the Treasury (Action on Smoking and Health, 2011). 
Research by Jarvis and Wardle (1999) found that tobacco dependency was strongly associated 
with social deprivation. Factors of social deprivation related to smoking are also linked to the 
course of mental illness and include low income, poor education and unemployment (Mallet, 
2013).These factors as noted by Jarvis and Wardle (1999) are diverse and adverse in relation to 
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the individual’s environment. Research carried out in general population found that excessive 
smoking rates are higher in lower social economic groups with a significant proportion of smokers 
with  serious mental health illness overrepresented in this group and are unable able to work, 
have limited income and are socially isolated; no wonder patients residing in psychiatric 
institutions often report boredom as a reason for excessive smoking (Clenaghan, 2010; Dunstan, 
2010).In the United States, the national health interview survey found psycho-social stress is 
associated with excessive smoking rates among individuals from deprived areas (Lawrence et al. 
2009). Gillam et al. (2012) argue that ‘health inequalities are socially determined and reflect 
unequal distribution of power, income, goods and services’. Smokers with SMI who are over 
represented in lower social economic groups have a low uptake of health and social care 
interventions. Possibly, this is due to complex psychosocial challenges and the stigma of living 
with mental illness which in turn contributes significantly to the main causes of ill-health and 
mortality in this group, with the rates of cancer, heart disease and respiratory diseases among 
this group double those in the general population (Health Development Agency, 2004; Action on 
Smoking and Health,2013; Mental Health Foundation, 2016).  
Research evidence supports the existence of genetic associations between major depression 
and tobacco dependency. A study of Finnish twins found a modest genetic correlation (Korhonen, 
et al. 2007); findings of a co-twin control and bivariate design study in the United States found 
that chronic smoking and major depression were significantly genetically connected (Hitsman, et 
al. 2009). Similarly, Kendler, et al. (1993) found a moderate genetic relationship between major 
depression and continued tobacco use and even a stronger relationship between depression, 
schizophrenia and tobacco dependence in men was reported. Perhaps, the interplay between 
genetic vulnerability and environmental risk factors may explain an individual’s craving for 
smoking. 
 Statutory and policy initiatives 
A review by Department of Health (1993) found that advertising impacted positively on smoking 
related behaviour, with advertising seen to increase tobacco consumption. As well as the 
Broadcasting Acts of 1990 and 1996 which prohibited tobacco advertising on television and radio, 
in 2003 the Labour government legislated to ban cigarette advertising on billboards. 
Unsurprisingly, Action on smoking and health (2015) reported that internal Tobacco company 
findings indicated that people are more inclined to smoke the most heavily-promoted brands. 
Consequently, the UK government in May 2016 introduced a law requiring standard packaging of 
tobacco products- this was in part made possible by the relentless lobbying of the public health 
community. This strategy has not been without its limitations as the Tobacco industry is adopting 
less regulated advertising avenues (internet) to promote their products (Bach, 2016).  
Furthermore, the subsequent passing of the Health Care Act in 2006 was followed in July 2008 
by a complete ban on smoking in mental health settings. The Mental Health Foundation (2008) 
conducted a survey in a range of psychiatric units to evaluate the implementation of the ban, of 
the 120 responses from 100 NHS centres, 15.6% found the ban was totally effective, 72.5% 
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reported partial effectiveness while 11.9% reported that the ban was not effective at all. Recently, 
Robson et al. (2017) found that introduction of the smoking ban in mental health settings 
appeared to reduce the incidence of physical assaults and there has been an increased provision 
of cessation therapies and training for staff. 
Following the publication of the “Tobacco Control Plan” by the coalition government in 2011, 
(Public Health England, 2015), in February 2017, a cross party cluster of peers called on the UK 
government to publish the Tobacco control strategy without further postponement and, a new 
plan “Towards a smoke-free generation: tobacco control plan for England” was published in July 
2017 (Department of Health 2017). Under the Tobacco control plans of 2011, 2017 and the 
Health Care Act 2013, NHS and social care providers are tasked to commission services to 
address tobacco dependency in the general population and to foster inter-service working 
partnerships aimed at addressing inequalities and improving access to health interventions. 
However, austerity measures across public sector services which have resulted into cutting 
effective social and health protection programmes that mitigate risks to health has led to 
reduction in health coverage and impacted on inter-service working dynamics. 
NHS stop smoking services  
While mental health settings have been sluggish to implement smoking cessation support for 
individuals with SMI, these patients are known to be motivated to quit compared to people without 
mental illness (Campion et al. 2008; McNeill and Szatkowski; 2013; World Health 
Organisation,2013; Public Health England, 2015). The NHS Stop Smoking Services have been 
appraised as cost effective in providing support for individuals to reduce and /or quit smoking 
through group or one-to-one individualised support (Health and Social Care Information Centre 
2015). The services are widely available via public and third sector agencies and, are provided by 
trained specialist smoking cessation advisors. Action on Smoking and Health (2011) report found 
that effectively trained staff can facilitate early screening and monitoring for unhealthy lifestyle 
behaviours such as smoking. Several mental health settings have significantly increased uptake 
of training for staff to deliver cessation interventions but uptake for some remains low (Public 
Health England, 2015). Following the launch of the NHS stop smoking services, there has been 
increased accessibility of cessation interventions in the primary care sector via health centres, 
pharmacies, General practice and third sector. In general practice at least 1 in 5 of the people 
seen every day are smokers (Rodman and Gaduzo, 2015). There is evidence that advice and 
behaviour support given by GPs and primary care staff is effective (Public Health England 2015). 
The NHS Making Every Contact Count (MECC) programme emphasises staff, NHS and social 
care providers’ readiness to support people to improve their health and wellbeing through 
behaviour change (Varley and Murfin (2014). Recently, more government policies for example 
the ‘NHS Five Year Forward View For Mental Health’ highlight the need for health professionals 
to facilitate screening and offer lifestyle interventions and/ or refer patients who require support to 
specialist services i.e. smoking cessation (NHS England, 2017; NICE, 2013). In general practice, 
this is reflected in contractual changes since 2004 in the General Medical Services contract (the 
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Quality and Outcomes Framework (QOF)) where points and financial incentives are awarded for 
recording patients’ smoking status, providing cessation advice or referrals. 
 A range of interventions are offered in the NHS stop smoking services including opportunistic 
brief advice, psychological support and information giving (posters, leaflets) to raise awareness of 
cessation services and benefits of quitting. Brief and routine intervention offered is pro-active and 
person centred considering the individual’s needs and access to pharmacotherapies (Nicotine 
replacement therapies(NRT), lozenges, gum, patches, nasal sprays, bupropion and Verenicline) 
if required (National Institute for Health and Clinical Excellence, 2013).  
While the average cessation rate for NHS stop services is normally 50% at week four, for 
smokers with SMI, Godfrey et al. (2005) argue that the traditional ‘four weeks’ quit attempt maybe 
inadequate support and that smokers with SMI often require enhanced support to quit. Factors 
such as unemployment, social isolation, poverty and stigma of mental illness common in 
individuals with SMI serve as barriers to successful implementation of health interventions this 
population (Royal College of Psychiatrists, 2013). Therefore, it is prudent to consider these and 
other health determinants first when conducting health assessments and monitoring. Holistic care 
planning needs to consider the effects of smoking on the mental wellbeing of patients and 
especially the link between smoking and increased metabolism of drugs used in mental health. 
Combination of pharmacotherapy, individual and group therapy 
Behavioural interventions for smoking cessation augment the benefits of pharmacotherapy in 
individuals with SMI and improve mood states during and after quitting attempts (Ferguson et al. 
2003). Group and individual therapy is more effective than self-help (Wang et al. 2008; Lancaster 
and Stead, 2005; Roberts et al. 2013) and the quit success rate increases by up to 70% when 
pharmacotherapy (Bupropion, NRT) is combined with either group or individual therapy (Aveyard 
et al. 2012; Health and Social Care Information Centre, 2015). West et al. (2004) found high 
cessation rates when brief advice and NRT was used in inpatients in mental health settings; the 
uptake of the two interventions is more common in mental health settings due to the relatively low 
cost (Public Health England 2015). Individuals with SMI can benefit from both NRT and 
behavioural support. However, too often mental health professionals are reluctant to facilitate 
these therapies in practice (Sharma et al. 2016).  
A case study of 700 smokers with mental illness in a London NHS Trust found that 30% had quit 
and/or reduced tobacco use significantly following a 12-weekly intervention program involving 
brief advice, behavioural therapy, pharmacotherapy and follow up support within inpatient and 
community settings (Clenaghan, 2010). Training to deliver cessation interventions equipped staff 
on this project with skills to facilitate opportunistic screening, monitoring and follow up support. 
Action on Smoking and Health (2015) argue that to deliver cessation interventions effectively, 
provider services must invest in staff training and education, equally Hughes (2007), supports this 
view and emphasises that mental health nurses are well-placed to intervene with individuals with 
SMI. 
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In their study examining quit support interventions amongst smokers with psychotic disorders in 
the community, Baker et al. (2006) found that the smoking abstinence rate at the end of the trial 
(36 weeks) was significantly higher in participants who received a combination of (NRT, cognitive 
behaviour therapy) compared to routine care. Also, individual therapy and NRT versus routine 
care offered led to reduction of cigarettes smoked per day from baseline (Baker et al. 2006). 
Similarly, findings from a study of 844 smokers with mental illness found that cessation rates in 
individuals who received supportive care (motivational interviewing, individual counselling) were 
higher when NRT was added, with almost 60% who completed the programme having 
successively quit (Ashton et al. 2015). Individual or group therapy should consider assessment 
for other unhealthy lifestyle behaviours such as alcohol misuse alongside smoking as part of 
holistic care planning (Stead and Lancaster, 2005; Ingram et al. 2017). 
A systematic review of smoking cessation interventions among people suffering from 
schizophrenia found increased cessation rates when bupropion is used alone. However, when 
combined with NRT, individual and/or group counselling, smoking abstinence increased without 
endangering mental state (Tsoi et al. 2010). Equally, two reviews of interventions combining 
(NRT, behavioural therapy) among depressed patients reported increased abstinence rates and 
reduction of depressive and anxiety symptoms (MacPherson et al. 2010). 
Mood states and smoking cessation 
Research conducted on negative mood states after quitting attempts is less convincing, but 
quitters commonly report depression and poor mood states as negative effects. MacPherson et 
al. (2010) support Mathew et al (2017) in that behavioural approaches aimed at mood 
management may be key strategies in managing smoking behaviour and any associated 
negative mood states following quitting. A clinical trial of 68 smokers with major depression found 
that combining behavioural therapy with NRT resulted in significant abstinence rates than NRT 
alone during a 6 months follow up period. Participants who received a behavioural intervention 
reported lower depressive symptoms (MacPherson et al. 2010). A recent meta-analysis found 
that quitting smoking is linked to improved quality of life and reduced depression, stress and 
anxiety (Taylor et al. 2014). Recently, Mathew et al. (2017) have argued for a holistic assessment 
for the individual’s health beliefs and symptoms of their mental illness and an evaluation of how 
the latter impacts on their smoking behaviour and mood. This knowledge could assist clinicians to 
individualise cessation support for smokers with SMI. Mathew and colleagues further contend 
that the incentive learning theory can engender our understanding of mental illness and how it 
might impact on tailored support in relation to unhealthy lifestyle behaviours such as smoking. 
 Nicotine Replacement Therapy (NRT), Bupropion and Varenicline 
A review by Wang et al. (2008) found that the use of NRT while smoking considerably increases 
the abstinence rates; smokers with mental illness struggle to stop and could benefit from additive 
NRT use while they smoke.  Stead et al. (2008) also claim that combining a nicotine patch with a 
rapid-delivery (nasal spray) form of NRT was found to be more effective than a single type of 
NRT. Moreover, the study findings indicate that the risk ratio of abstinence for any type of NRT 
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compared with control was 1.58 with considerably higher risk ratios of abstinence for (patch, 
tablets, and lozenges) than gum.  
A review of randomised trials compared use of NRT to placebo; the findings show that all types of 
NRT increased by up to 70% the likelihood of quitting although no evidence was found for overall 
difference in effectiveness between different types of NRT (Stead et al. 2012).Higher abstinent 
rates were recorded when bupropion was combined with NRT in smokers with mental illness and 
in their study examining the effectiveness of bupropion amongst smokers with post-traumatic 
stress disorder (PTSD), Hertzberg et al (2001) found that 80% of smokers prescribed bupropion 
successfully quit. Similarly, George et al. (2008) found that the use of bupropion almost doubles 
the odds of quitting smoking after six months when used as a single pharmacotherapy). In their 
review of cessation smoking interventions among smokers with SMI, Banham and Gilbody (2010) 
found that combining bupropion with NRT improves quit rates and that all pharmacological 
interventions are of benefit to smokers with SMI than placebo. Similarly, a systematic review of 
use varenicline and bupropion to help smokers with SMI to stop smoking found that both are 
effective and tolerable for smoking cessation (Koegelenberg et al. 2014).  
Historically, the use of varenicline and bupropion among smokers with SMI has been linked to 
increased neuropsychiatric reactions and drug interactions and possibly, the above factors could 
explain low uptake and availability of both therapies in mental health settings. However, 
subsequent findings following a study of 8144 smokers with SMI found that varenicline increased 
smoking cessation in smokers without exacerbating mental illness. Equally, findings of a 
randomised study found that the use of varenicline and/ or bupropion in people with SMI did not 
show a significant increase in neuropsychiatric adverse events (Anthenelli et al. 2016). Further 
research shows that there is no evidence linking suicide or cardiac events to Varenicline and 
bupropion, the authors concluded that these smoking cessation therapies are effective and 
should be made more widely available in mental health settings (Cahill et al. 2008; Ware et al. 
2013; Hall and Prochaska 2009). Other research findings suggest that it is safe and effective to 
combine varenicline and NRT and / or bupropion to maximise cessation rates among smokers 
(Ebbert et al. 2009; Koegelenberg et al. 2014; Taylor et al. 2015). Nonetheless, if patients taking 
varenicline or bupropion develop anxiety, depressed mood, suicidality or exhibit any changes in 
behaviour, both drugs should be stopped, and they should be medically reviewed immediately 
(Campion et al. 2017). 
Implications for practice 
Despite overwhelming research evidence about the dangers of smoking, several mental health 
staff exhibit reluctance to engage patients about smoking and harbour negative perceptions of 
patients’ motivation and willingness to stop smoking. Smoking cessation interventions which are 
effective in the population are also known to work in smokers with SMI, suggesting that mental 
health professionals should target cessation interventions towards smokers with SMI. Staff 
training, and education is essential to ameliorate such attitudes as the lack of enthusiasm among 
staff is likely to have an impact on patients as opportunistic advice from health professionals has 
8 
 
been shown to positively influence quit attempts in smokers (Department of Health 2017; 
Ratschen et al. 2011). Training frontline staff is essential to develop skills, knowledge and 
confidence to engage patients and for staff to feel enabled to offer cessation support. 
Additionally, this foundation could help engage patients and staff alike to challenging the lax 
smoking culture entrenched in mental health settings. 
Increasing the knowledge of mental health staff about nicotine dependency, smoking, 
interventions and the interaction with psychotropic medication could enhance the support and 
advice mental health professionals provide to patients to quit smoking. Smoking has been found 
to decrease blood levels of antipsychotic and stopping smoking could low the dose needed. 
Smoking can make antipsychotic drugs less effective, resulting in increased dosages to have the 
same therapeutic effect and possibly more side effects for smokers with SMI on antipsychotic 
drugs. Patients on clozapine who smoke require close monitoring as doses may need to be 
titrated up if the patient smokes or reduced during and/or after quit attempt. It is important 
therefore to tailor support individually to each patient and to consider varied needs that influence 
the patient’s health and wellbeing. 
Smokers with SMI benefit from enhanced support which should be longer than the traditional ‘four 
weeks’ quit attempt (Nohlert et al. 2013; Royal College of Psychiatrists, 2013). Increased quit 
rates occur if interventions are adapted to the needs of patients with mental health conditions 
(Roberts et al. 2016). Arguably, there is need for adequate and consistent support to sustain quit 
attempts by considering factors such as polypharmacy, physical health and social-environmental 
factors (Wang et al. 2008). While the self –medication theory is broadly believed by mental health 
professionals, making a quit attempt has been found to improve mental health in the long term 
and, smoking is not an effective way of managing mental illness (Taylor et al. 2014). 
Most frequently reported adverse events for varenicline are headache, insomnia, abnormal 
dreams. Gradual titration may improve tolerability when used in smokers with SMI. There are no 
serious neuropsychiatric symptoms with either varenicline or bupropion relative to nicotine patch 
or placebo reported in those with or without mental illness and that both therapies are effective 
and tolerable for smoking cessation in smokers with SMI (Anthenelli et al. 2016). Therefore, these 
therapies should be made more widely available in mental health settings than is currently 
practiced. Behavioural support and pharmacological interventions discussed in this article have 
been recommended by the National Institute for Health and Clinical Excellence (2013) and should 
be used for up to nine to twelve weeks with longer use known to be safe and still of good value in 
most smokers. 
Many smokers with SMI are concerned about their tobacco use and want help (Szatkowski and 
McNeill, 2013; Ashton et al. 2014). If smokers with SMI are given good information and support, 
many can quit. Morris et al. (2011) studied a 10-session community based group programme 
involving 87 smokers with SMI and found that a smoking cessation rate of 10% by patients who 
participated and received information. Similarly, in a north London Mental Health Trust, emphasis 
has been on raising awareness of cessation services and highlighting benefits of quitting through 
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information giving and supporting individuals to make healthy life choices (Clenaghan, 2010). The 
structured smoking cessation approaches to screening and monitoring, such as the  “four A`s”, 
Ask, Advice, Assist and Arrange (West et al. 2000) which sets out clear stages and goals for 
interventions are particularly useful in motivating smokers. Research evidence shows that 95% of 
patients expect to be questioned about their smoking behaviour and a brief intervention adopting 
such evidence based frameworks can be significant (McClave et al. 2010). These approaches put 
the patient in the ‘driving sit’, emphasising self-control and elicits ‘self-Motivating’ statements 
often used to assess behaviour change and motivation (Rosengren, 2009; Stead et al. 2008; 
Prochaska, 2011). As well as smoking, mental health professionals should engage patients 
around other lifestyles factors such as alcohol use, weight management, and drug and substance 
misuse. Smokers drink twice as much alcohol as non-smokers (Rigotti et al. 2012; Prochaska et 
al. 2013).  
In preparing this paper, the author has found that the literature around the uptake of smoking 
cessation support for smokers with SMI is limited; targeted improvements around the planning 
and delivery of cessation support could be enhanced further through future research to evaluate 
the uptake of cessation support and the frequency of the rate of delivery of cessation therapies 
towards amongst smokers with SMI. 
Conclusion 
Smoking is the largest avoidable cause of premature death and poor health in United Kingdom 
and Globally. The incidence of cancers and other smoking related diseases in people with SMI 
remains extremely high with disproportionate levels of smoking related morbidity and mortality. 
Smoking cessation therapies which are known to work in the general population are equally as 
effective in smokers with SMI. Therefore, it is of vital importance for mental health professionals 
to facilitate these effective cessation therapies towards patients to address the excessive 
smoking rates among this patient group.  
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